Recent advances in bioinorganic chemistry of bismuth

Li, Hongyan; Sun, Hongzhe

doi:10.1016/j.cbpa.2012.01.006

Cited by 163 publications

(66 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…bismuth | drug selectivity | glutathione | MRP | positive feedback B ismuth (Bi) compounds have been used in clinical medicine for over a century in various infectious diseases (1)(2)(3)(4). Together with antibiotics, bismuth drugs such as bismuth subsalicylate (Pepto-Bismol) and colloidal bismuth subcitrate (CBS; De-Nol) are used to treat Helicobacter pylori infection and gastrointestinal disorder (5)(6)(7).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells

Hong

Lai²,

Chan

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

View full text Add to dashboard Cite

Glutathione and multidrug resistance protein (MRP) play an important role on the metabolism of a variety of drugs. Bismuth drugs have been used to treat gastrointestinal disorder and Helicobacter pylori infection for decades without exerting acute toxicity. They were found to interact with a wide variety of biomolecules, but the major metabolic pathway remains unknown. For the first time (to our knowledge), we systematically and quantitatively studied the metabolism of bismuth in human cells. Our data demonstrated that over 90% of bismuth was passively absorbed, conjugated to glutathione, and transported into vesicles by MRP transporter. Mathematical modeling of the system reveals an interesting phenomenon. Passively absorbed bismuth consumes intracellular glutathione, which therefore activates de novo biosynthesis of glutathione. Reciprocally, sequestration by glutathione facilitates the passive uptake of bismuth and thus completes a self-sustaining positive feedback circle. This mechanism robustly removes bismuth from both intra-and extracellular space, protecting critical systems of human body from acute toxicity. It elucidates the selectivity of bismuth drugs between human and pathogens that lack of glutathione, such as Helicobacter pylori, opening new horizons for further drug development.bismuth | drug selectivity | glutathione | MRP | positive feedback

show abstract

mentioning

confidence: 99%

“…Low uptake of bismuth by human gastrointestinal tract (GIT) was often considered as the reason of bismuth's low toxicity (1). However, it contradicted the fact that no severe toxicity appeared, even when bismuth was repeatedly injected intramuscularly to treat syphilis (9).…”

mentioning

confidence: 99%

Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells

Hong

Lai²,

Chan

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bismuth compounds with antimicrobial and anticancer activities have been reviewed recently. [65] The group of Sun and co-workers uncovered that glutathione binds Bi(III) in human cells and compartmentalizes it into subcellular vesicles, effectively removing it from intra-and extracellular compartments. [66] Over the years, the use of GE-ICP-MS techniques and customized fluorescent probes has facilitated the identification of a number of Bi-binding proteins.…”

Section: Bismuthmentioning

confidence: 99%

Metal Complexes, an Untapped Source of Antibiotic Potential?

2020

View full text Add to dashboard Cite

With the widespread rise of antimicrobial resistance, most traditional sources for new drug compounds have been explored intensively for new classes of antibiotics. Meanwhile, metal complexes have long had only a niche presence in the medicinal chemistry landscape, despite some compounds, such as the anticancer drug cisplatin, having had a profound impact and still being used extensively in cancer treatments today. Indeed, metal complexes have been largely ignored for antibiotic development. This is surprising as metal compounds have access to unique modes of action and exist in a wider range of three-dimensional geometries than purely organic compounds. These properties make them interesting starting points for the development of new drugs. In this perspective article, the encouraging work that has been done on antimicrobial metal complexes, mainly over the last decade, is highlighted. Promising metal complexes, their activity profiles, and possible modes of action are discussed and issues that remain to be addressed are emphasized.Antibiotics 2020, 9, 90 2 of 24 Metal-containing compounds have played a small but seminal role in medicinal chemistry of throughout the 20th century. An arsenic-containing compound, Salvarsan, was discovered at the beginning of the century and became the first effective treatment of syphilis [9]. It was however the discovery of the anticancer drug cisplatin and its successors that really kickstarted the field of inorganic medicinal chemistry. Even today, platinum-based chemotherapeutics are still used in the majority of cancer treatments [10]. The gold-containing auranofin is an approved drug for the treatment of rheumatoid arthritis and is currently under investigation for its anticancer as well as antimicrobial properties [11][12][13][14][15][16]. Invigorated by these breakthrough successes, the field has expanded to many other elements in the last few decades, with complexes of titanium, iron, ruthenium, gallium, palladium, silver, gold, bismuth, and copper entering clinical trials [17][18][19][20][21][22]. The medicinal applications of these metal complexes range from anticancer to antimalaria over to neurodegenerative diseases. Strangely, antibacterial applications are remarkably sparse in this list and the number of literature reports on metal-based antimicrobials is dwarfed by the much more frequent publications on metal-based anticancer compounds. This is surprising as metals such as bismuth and silver have long been known to possess antibacterial properties. Some medicinal products are currently available. There are however a variety of products, such as silver-coated underwear, with a more dubious scientific basis. Nevertheless, the systematic evaluation of the antimicrobial properties of metal complexes has increased in pace over the last decade, with several reports highlighting the activity and potential modes of action of metal-based antibiotics. This perspective article will discuss the major discoveries in the non-traditional field of metal complex-based antibiotic co...

show abstract

“…Bi, as aheavy metal, is stable to both dry and moist air at ordinary temperatures and has unusually low toxicity. [3] Since the late 18th century,B i-based NMs, especially organobismuth compounds, have been used in medicine for treatment of various gastrointestinal diseases, [4] such as gastritis, [5] dyspepsia, [6] ulcers and H. pylori infection. [7] Moreover,t hese organobismuth compounds have been also used as antimicrobial and antileishmanial agents.…”

Section: Introductionmentioning

confidence: 99%

Novel Bismuth‐Based Nanomaterials Used for Cancer Diagnosis and Therapy

Cheng

Zhang

2018

Chemistry A European J

View full text Add to dashboard Cite

Theranostic nanomaterials (NMs) have gained increasing attention for their simultaneous performance of diagnosis and therapy. Bi-based NMs hold great potential as theranostic platforms based on their X-ray sensitive capability, near-infrared driven semiconductor properties, and distinctive structures, which facilitate the computed tomography (CT) imaging, photoacoustic (PA) imaging, radiation therapy, and phototherapy. The sophisticated design in composition, structure, and surface fabrication of Bi-based NMs can endow these NMs with more modalities in cancer diagnosis and therapy. In this Minireview, we focus on the recent advances in Bi-based theranostic NMs. A series of unique structures and functions as well as the underlying property-activity relationship of Bi-based NMs are showcased to highlight their promising imaging and therapeutic performance. At the end, we propose some challenges for the design and preparation of Bi-based NMs to improve their cancer diagnostic and therapeutic performance.

show abstract

Recent advances in bioinorganic chemistry of bismuth

Cited by 163 publications

References 56 publications

Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells

Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells

Metal Complexes, an Untapped Source of Antibiotic Potential?

Novel Bismuth‐Based Nanomaterials Used for Cancer Diagnosis and Therapy

Contact Info

Product

Resources

About